Puma Biotechnology, Inc. (Nasdaq: PBYI) expanded the fourth cohort from its Phase II SUMMIT clinical trial of its lead drug ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE